Intol, Jessa Mae C.
HRN: 21-27-14 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/19/2022
CEFUROXIME 500MG (TAB)
04/19/2022
04/25/2022
PO
500mg
BID X 7 Days
WBC: 14.4; S/p LTCS Secondary To Placenta Previa
Waiting Final Action
Indication: Empirical De-escalation Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes